Trial · NCT07906119
Acceptance and Commitment Therapy-Based Group Psychotherapy for Chronic Headache
NCT07906119, Not applicable, Active not recruiting, Saglik Bilimleri Universitesi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acceptance and Commitment Therapy-Based Group Psychotherapy for Chronic Headache. Trials, record NCT07906119. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906119
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acceptance and Commitment Therapy-Based Group Psychotherapy for Chronic Headache
- NCT number
- NCT07906119
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 72 participants, actual
- Lead sponsor
- Saglik Bilimleri Universitesi
- Conditions
- Chronic Headache
- Interventions
- Acceptance and Commitment Therapy-Based Group Psychotherapy, Psychoeducation
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Depression and Anxiety Levels Assessed by the Depression Anxiety Stress Scales-21 (DASS-21) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Depression Anxiety Stress Scales-21 (DASS-21) is a 21-item self-report measure and a shortened version of the original 42-item Depression Anxiety Stress Scales (DASS-42). It consists of three 7-item subscales assessing depression, anxiety, and stress. Each item is rated from 0 to 3. For each subscale, the seven item scores are summed to obtain a raw score ranging from 0 to 21, and the raw score is then multiplied by 2 to obtain the final subscale score ranging from 0 to 42. In this study, the Depression and Anxiety subscale scores are evaluated. Higher scores indicate greater symptom severity and therefore a worse outcome. |
| Primary | Change in Headache Impact Assessed by the Headache Impact Test-6 (HIT-6) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Headache Impact Test-6 (HIT-6) is a 6-item self-report measure assessing the impact of headache on daily life, including pain, social functioning, role limitations, cognitive functioning, psychological distress, and vitality. Total scores range from 36 to 78, with higher scores indicating a greater negative impact of headache on daily life and therefore a worse outcome. |
| Primary | Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey (SF-12) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Short Form-12 Health Survey (SF-12) is a 12-item measure assessing health-related quality of life. It provides Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Standardized scores range from 0 to 100, with higher scores indicating better health-related quality of life and therefore a better outcome. |
| Secondary | Change in Psychological Flexibility and Experiential Avoidance Assessed by the Acceptance and Action Questionnaire-II (AAQ-II) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Acceptance and Action Questionnaire-II (AAQ-II) is a 7-item self-report measure assessing experiential avoidance and psychological flexibility. Each item is rated from 1 to 7, resulting in a total score ranging from 7 to 49. Higher scores indicate greater experiential avoidance and lower psychological flexibility and therefore a worse outcome. |
| Secondary | Change in Engaged Living Assessed by the Engaged Living Scale (ELS) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Engaged Living Scale (ELS) is a 16-item self-report measure assessing engagement with personal values and life fulfillment. It consists of Valued Living and Life Fulfillment subscales. Each item is rated from 1 to 5, resulting in a total score ranging from 16 to 80. Higher scores indicate greater engaged living, including greater engagement with personal values and life fulfillment, and therefore a better outcome. |
| Secondary | Change in Pain Intensity Assessed by the Visual Analog Scale (VAS) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Visual Analog Scale (VAS) assesses subjective pain intensity on a scale ranging from 0 to 10, where 0 represents no pain and 10 represents unbearable or the worst possible pain. Higher scores indicate greater pain intensity and therefore a worse outcome. |
| Secondary | Psychotherapy Satisfaction | 1 month after the final session | Psychotherapy satisfaction is assessed using a measure consisting of five closed-ended questions rated from 1 (not at all) to 4 (completely), together with one open-ended question about participants' views of the psychotherapy process. Higher ratings on the closed-ended questions indicate greater psychotherapy satisfaction. The open-ended question is not scored. |
| Secondary | Change in Repetitive Negative Thinking Assessed by the Perseverative Thinking Questionnaire (PTQ) | Baseline (before the first group session), at the end of the fourth session (up to 1 month) and 1 month after the final session | The Perseverative Thinking Questionnaire (PTQ) is a 15-item self-report measure assessing repetitive negative thinking independent of thought content. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 60. Higher scores indicate greater repetitive negative thinking and therefore a worse outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906119
GET https://conductscience.org/api/trials/v1/NCT07906119/registered